BCYC IPOs 4.98M* ADSs @$14.00: https://www.businesswire.com/news/home/20190522005905/en Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops that stabilize their structural geometry. *Assuming exercise of underwriter’s option.